A first treatment for vitiligo available in France. Opzelura cream, developed by the American laboratory Incyte Biosciences.
It is already available in the United States, Germany and Austria. The French Vitiligo Association estimates that around 1 to 2% of the world's population is affected by this very visible chronic disease which can lead to a "significant alteration in the quality of life, in relationships with others and with oneself" More than a million people in France are affected by the pathology.